Novartis
NICE rejects Glivec as adjuvant therapy
June 24, 2010Sales and Marketing Glivec, NICE, Novartis
NICE has rejected the use of Novartis’ Glivec as an adjuvant treatment for people who have had a gastrointestinal stromal …
Digital Pharma: Playing healthcare games
June 23, 2010Medical Communications Boehringer, Novartis, diabetes, digi game, malaria, virtual games
Boehringer Ingelheim has become the latest pharma company to use an online game to raise disease awareness. The pharma company …
Tasigna more effective than Glivec, says Novartis
June 21, 2010Research and Development, Sales and Marketing Glivec, Novartis, Tasigna, leukaemia
Novartis has gained US approval for Tasigna to be used as a front line treatment for chronic myeloid leukaemia. The …
Lucentis boosted by diabetic vision study
May 24, 2010Research and Development, Sales and Marketing AMD, DME, Lucentis, Novartis
A phase III trial of Novartis’ ranibizumab has shown it to be superior at promoting vision gain in patients with …
Novartis shines in first quarter
April 21, 2010Sales and Marketing 2010 financials, Alcon, Novartis
Novartis has had a very strong first quarter, its first under new chief executive Joe Jimenez, delivering a 25% increase …
Novartis set to boost generic portfolio
April 19, 2010Sales and Marketing Novartis, Sandoz, generics
Novartis’ generics arm Sandoz has signed a deal to acquire US-based inhalable drug specialist Oriel Therapeutics. Sandoz will gain rights …
Gilenia cuts relapse rates in MS patients
April 14, 2010Sales and Marketing Gilena, MS, Novartis
Novartis’ new oral multiple sclerosis treatment Gilenia has been shown to reduce relapse rates significantly in new trial data.Data presented …
NICE seeks compromise over Glivec approval
March 24, 2010Sales and Marketing Glivec, NICE, Novartis
NICE says it is unlikely to approve the use of Glivec against gastrointestinal stromal tumours (GISTs) after surgery, but is …
Digital Pharma: Novartis’ transplant community
March 19, 2010Medical Communications Novartis, PatientsLikeMe, community, digital pharma, digital pharma research, patient information
Novartis has become the second pharma company to partner with PatientsLikeMe on an online community, working with the site on …
Tekturna fails to show heart attack benefit
March 17, 2010Research and Development Diovan, Novartis, Tekturna, hypertension
Novartis’ hypertension treatment Tekturna has failed to show it helps patients recover from a heart attack when added to standard …
Novartis buys into Transgene’s lung cancer candidate
March 11, 2010Research and Development Novartis, Transgene, immunotherapy, lung cancer
French biotech company Transgene has signed a deal with Novartis for the future development and marketing of its potential lung …
Digital Pharma: Novartis tells cystic fibrosis stories
February 25, 2010Medical Communications Novartis, cystic fibrosis, digi, digi pharma, social media
Novartis has launched a new disease awareness campaign for cystic fibrosis that blurs the lines between fact and fiction. Its …
Novartis gains edge in MS treatment race
February 22, 2010Research and Development, Sales and Marketing Cladribine, Gilenia, MS, Novartis
Novartis’ new oral multiple sclerosis treatment Gilenia will be given a priority review by the FDA.This could lead to a …
NICE warns industry on cost-effectiveness
February 9, 2010Sales and Marketing BMS, Janssen, NICE, Novartis, hta
NICE has turned down three drugs on cost grounds and has urged the pharma industry to do more to help …
Working Life: Olivier Leupin
February 9, 2010Business Services, Research and Development Novartis, Working Life, careers, careers voice
How did you find your way into your most current role? After receiving a master’s degree in biology at the …
